We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Regular Thyroid Testing Recommended Regardless of Diabetes Type

By LabMedica International staff writers
Posted on 05 Mar 2020
Print article
Image: Biochemical thyroid screening is recommended as part of routine management for type 1 and type 2 diabetes (Photo courtesy of Alzyme).
Image: Biochemical thyroid screening is recommended as part of routine management for type 1 and type 2 diabetes (Photo courtesy of Alzyme).
Thyroid dysfunction is common among people with diabetes regardless of type, suggesting that biochemical thyroid screening should be a part of routine management for those with type 1 and type 2. A recent study has determined the prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults.

The American Diabetes Association (ADA) recommends universal screening for thyroid dysfunction in type 1 diabetes. The ADA previously recommended thyroid screening for women aged at least 50 years with type 2 diabetes; however, the current ADA guideline and that of the UK National Institute for Health and Care Excellence do not recommend thyroid function monitoring in type 2 diabetes.

Scientists at the University of Western Australia Medical School (Fremantle, Australia) in an observational study, analyzed data from 1,617 adults participating in the Fremantle Diabetes Study Phase II, including 130 (8%) with type 1 diabetes, 1,408 (87.1%) with type 2 diabetes and 79 (4.9%) with latent autoimmune diabetes in adults (LADA). The team assessed thyroid-stimulating hormone (TSH) and free thyroxine at baseline between 2008 and 2011 and in those attending follow-up at four years.

The investigators reported that the prevalence of known thyroid disease was 11.7% (189/1,617). Of the remaining 1,428 participants, 5.1% (73/1,428) had biochemical evidence of subclinical hypothyroidism, 1.1% (15/1428) overt hypothyroidism, 0.1% (2/1428) subclinical hyperthyroidism and 0.2% (3/1428) overt hyperthyroidism, representing an overall baseline prevalence of thyroid disease of 17.4% (282/1,617). During 5,694 patient‐years of follow‐up, 25 (3.0%) of the 844 with a normal baseline TSH and follow‐up data developed known thyroid disease. Of the remaining 819, 3.4% developed subclinical hypothyroidism, 0.2% overt hypothyroidism and 0.5% subclinical hyperthyroidism.

Paul Chubb, PhD, FFSc (RCPA), an adjunct associate professor and a co-author of the study said, “The prevalence of thyroid disease is about the same regardless of the type of diabetes, mainly because the average age of people with type 2 diabetes was higher than that of those with type 1 diabetes. However, we also found that mild abnormalities of thyroid function test results were frequently transient, so that appropriate repeat testing and careful interpretation of the results is needed if overdiagnosis is to be avoided.”

The authors concluded that thyroid dysfunction, known or detected through screening, is common in diabetes. These data suggest the need for periodic clinical and biochemical screening for thyroid disease in all types of diabetes. The study was published on January 27, 2020 in the journal Clinical Endocrinology.

Related Links:
University of Western Australia Medical School

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.